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a  b  s  t  r  a  c  t
The antagonists of tumour necrosis factor (anti-TNF) have been successfully used in sev-
eral  chronic inﬂammatory diseases such as Rheumatoid Arthritis (RA), but some studies
have observed the development of infections by intracellular pathogens in patients using
anti-TNF. We  report a case of a female patient with previous diagnosis of RA for 16 years
that  used several disease-modifying anti-rheumatic drugs (DMARDs) that resulted in treat-
ment  failure, and then was treated with inﬂiximab. After ﬁfteen days of the second dose,
the patient developed ventilatory-dependent chest pain, dry cough and dyspnea. She was
hospitalized, and the diagnosis of pneumonia by Legionella pneumophila was conﬁrmed by
the  presence of Legionella antigen in an urine test. TNF is an inﬂammatory cytokine that also
acts  inhibiting the bacterial growth of intracellular pathogens, and its inhibition seems to
increase susceptibility to these infections in some patients.
© 2014 Elsevier Editora Ltda. All rights reserved.
Pneumonia  por  Legionella  após  uso  de  Inﬂiximabe  em  paciente  com
Artrite  Reumatoide
alavras-chave:
egionella pneumophila
r  e  s  u  m  o
Os antagonistas do fator de necrose tumoral (anti-TNF) têm sido utilizados com sucesso em
várias doenc¸as inﬂamatórias crônicas, como artrite reumatoide (AR), mas  alguns estudos
ator alpha de necrose por tumor
rtrite reumatoide
nﬂiximabe
observaram a ocorrência de infecc¸ões por patógenos intracelulares em pacientes medicados
com  anti-TNF. Relatamos um caso de paciente mulher com diagnóstico prévio de AR durante
16  anos e que estava sendo medicada com várias drogas antirreumáticas modiﬁcadoras de
ndo como resultado o insucesso terapêutico, sendo em seguida tratadadoenc¸a  (DARMDs), tecom inﬂiximab. Depois de transcorridos 15 dias da segunda dose, a paciente foi acometida
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por dor torácica ventilatório-dependente, tosse seca e dispneia. Foi hospitalizada, e o diag-
nóstico de pneumonia por Legionella pneumophila foi conﬁrmado pela presenc¸a do antígeno
de  Legionella na urina. TNF é uma citocina inﬂamatória que também promove inibic¸ão
do  crescimento bacteriano de patógenos intracelulares, e sua inibic¸ão parece aumentar
a  sensibilidade a essas infecc¸ões em alguns pacientes.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Antagonists of tumor necrosis factor (anti-TNF) have shown
signiﬁcant changes in the course of a number of chronic
inﬂammatory diseases, such as Crohn’s disease, ankylosing
spondylitis and RA.1
The tumor necrosis factor- (TNF-)  is a proinﬂammatory
cytokine with multiple targets and interactions, but it has
a well-established role in the pathogenesis of rheumatoid
inﬂammation.
Besides this proinﬂammatory function in RA, TNF also
acts as a cellular defence mechanism against infections. Stud-
ies have observed that anti-TNF therapy may be related to
increased risk of infections by intracellular pathogens, includ-
ing Mycobacterium tuberculosis, Legionella pneumophila, Listeria
monocytogenes, Aspergillus fumigatus,  Histoplasma capsulatum
and Pneumocystis jiroveci.
The evidence supporting this association between anti-
TNF and increased risk of infections include case reports, epi-
demiological studies and experiments with animal models.2
We  report a case of Legionella pneumonia in a patient with
RA during the use of anti-TNF and discuss the main factors
possibly involved in the genesis of this type of infection.
Case  report
Female patient, 50 years-old, with a history of erosive RA
and rheumatoid factor-positivity for 16 years. The patient
made use of several disease-modifying antirheumatic drugs
(DMARDs), including hydroxychloroquine, sulfasalazine,
methotrexate (MTX), leﬂunomide, and combination therapy
with MTX  and 25 mg/week SC, and leﬂunomide 20 mg/day.
After treatment failure and gastrointestinal intolerance to
MTX, the patient began treatment with inﬂiximab.
Based on that, we  opted to introduce inﬂiximab associated
with leﬂunomide. On that occasion, the chest X-ray was nor-
mal, and PPD = 10 mm;  isoniazid 300 mg/day was introduced
as prevention against reactivation of latent tuberculosis.
Fifteen days after the second dose of inﬂiximab, the patient
developed fever, dry cough, ventilatory-dependent chest pain,
and dyspnea. She was admitted at the hospital presenting
hypoxemia and alveolar consolidations in the left hemitho-
rax (Fig. 1A). The bronchoalveolar lavage ﬂuid was negative
for acid-fast bacilli and fungi, as well as for HIV. A diagno-
sis of legionellosis was conﬁrmed by a positive search for L.
pneumophila antigen in urine.The patient experienced improvement after four weeks
of combined use of a macrolide and a quinolone (Fig. 1B),
remaining persistent activity (DAS28 > 5.1) despite thecombination of methotrexate and leﬂunomide used as
therapeutic option. One year after the resolution of the
infection, the patient restarted inﬂiximab, and since then, has
maintained clinical remission (DAS-28 < 2.6) without further
infectious complications.
Discussion
Anti-TNF drugs act, in general, by blocking TNF-. The use
of these drugs has provided excellent results. Its effects range
from symptomatic improvement in patients resistant to treat-
ment with DMARDs to the interruption of progression of joint
damage in RA.3
TNF is a cytokine with an important role in the defence
against intracellular microorganisms. It is produced by mono-
cytes and macrophages, stimulates nitric oxide production
and induces differentiation of macrophages in epithelioid
macrophages, which are necessary for the formation of gran-
ulomas. Macrophages and monocytes are also useful in the
recognition and destruction of any macrophages, and mono-
cytes are also useful in the recognition and destruction of any
intracellular pathogen able or unable of forming granulomas.
In addition, TNF is essential for maintaining the integrity of
the granuloma.4 Granuloma formation is essential to counter
infections and, thus, to prevent their spread. This becomes
particularly important in infections with Mycobacterium tuber-
culosis.
L. pneumophila is a facultative intracellular bacterium that
preferably invades and infects macrophages and monocytes.
Studies in animal models have shown that the infection of
macrophages by L. pneumophila induces the production of
proinﬂammatory cytokines, such as TNF and IL-1, and that the
addition of recombinant TNF to macrophages infected with L.
pneumophila results in a signiﬁcant resistance of these cells to
bacterial growth.5 The mechanism by which TNF reduces the
bacterial replication has not been fully clariﬁed; some suggest
that the cytokine acts synergistically with interferon-gamma
synthesized by T lymphocytes in the inhibition of bacterial
growth, aided by increased concentrations of nitric oxide and
by the depletion of intracellular iron induced by TNF activity.6
In addition to these aforementioned mechanisms, TNF also
appears to act mediating the induction of glutathione, a pow-
erful antioxidant. In this way, TNF would minimize the effects
of L. pneumophila- and hyperoxia-induced lung injury.7
After the introduction of anti-TNF in clinical practice, the
appearance of opportunistic infections and infections by intra-
cellular bacteria was observed. In vitro studies have concluded
that cultured macrophages treated with TNF showed resis-
tance to infection by L. pneumophila, but also noted that
this resistance decreased after administration of anti-TNF in
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Figure 1 – A. Chest radiograph showing extensive consolidation into the left hemithorax. B. Chest radiograph after
t nd l
t
p
m
b
o
a
t
o
a
t
a
F
i
t
t
8
e
o
i
a
T
a
t
e
s
C
T
r
1
1reatment with a macrolide and a quinolone (azithromycin a
hese cultures. In addition, animal models infected with L.
neumophila treated with anti-TNF exhibited persistent pneu-
onia, with greater numbers of infected macrophages and
acteria versus controls untreated with anti-TNF.8
Epidemiological studies suggesting an increased risk of
pportunistic infections in general in patients treated with
nti-TNF were published.9,10 Case reports and case series in
he literature called the attention of physicians to the devel-
pment of L. pneumophila infection in patients treated with
nti-TNF. Tubach et al. estimated that the relative risk of infec-
ion by L. pneumophila in patients treated with anti-TNF is
bout 16.5 times greater than in the general population in
rance.11
Most reports of L. pneumophila infection are associated with
nﬂiximab. The same pattern is conﬁrmed when we refer to M.
uberculosis infection. Data from the Food and Drug Adminis-
ration (FDA) show that the incidence of this infection may be
 to 9 times greater in patients treated with inﬂiximab versus
tanercept.
The anti-TNF drugs mentioned have different mechanisms
f action, which may partly explain the difference in the
ncidence of infections. Inﬂiximab, by being a monoclonal
ntibody, forms more  stable and irreversible bonds with the
NF bound to cell membrane. Etanercept, which behaves like
 soluble TNF receptor, forms complexes less cytokine-avid.12
Therefore, physicians should be alert to the diagnosis of
his disease in patients treated with anti-TNF. Despite the well
stablished effectiveness and safety of these drugs, potentially
erious side effects should be monitored.
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